Lung cancer

Lung cancer
2020-01-20T00:00:00.000+08:00
Ongoing

EA5181

EA5181
Lung Cancer

Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable

Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable

Trial overview

Topic

EA5181

Disease

Lung cancer treatment and diagnosis

Description

Primary Objective: The primary objective of the trial is to determine whether concurrent MEDI4736 (durvalumab) with cytoxic chemo/radiation improves overall survival (OS) in addition to a standard therapy (chemotherapy and radiation followed by consolidative MEDI4736 (durvalumab)). Secondary objectives include estimation of progression-free survival, best objective response, incidence of local/distant progression, and toxicity. Patient Population: Patients with unresectable Stage 3 Non-small cell lung cancer.

Contact

Florida

Peggy Mouradian

Florida Peggy Mouradian ::: (954) 370-7555

Physicians

Eduardo B. Fernandez

MD, PhD, DABR, FACRO, FASTRO

Radiation Oncologist

Aventura (Radiation oncology) +2

Christopher T. Chen

MD, FACRO

Radiation Oncologist

Pembroke Pines (Radiation oncology) +2